BackIntec Pharma Overview

Intec Pharma Current Cash

Intec Pharma's current cash is $10M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$10.13M
↓ 6.95% YoYΔ $-757000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Intec Pharma Current Cash History

Loading

Intec Pharma vs. peers: Current Cash Comparison

Loading

Intec Pharma Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Intec Pharma (NTEC) FAQ

Intec Pharma (NTEC) currently reports a current cash of $10M as of March 2021. That compares with $11M in the prior-year period — down 7.0% year over year. Use the charts on this page to explore Intec Pharma's current cash history and peer comparisons.

Intec Pharma's current cash decreased from $11M to $10M — a 7.0% year-over-year decrease (period ending March 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Intec Pharma reported $10M in current cash as of March 2021. That compares with $11M in the prior-year period — down 7.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $10M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Intec Pharma, and consider following NTEC for alerts when major investors trade the stock.

Intec Pharma is classified in the Healthcare sector. On current cash, it currently shows $10M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NTEC with unrelated industries.